Novolog (NVLG) AI Stock Analysis

• Market Cap: 710.12M
• Dividend Yield: 5.59%
• Average Volume (3M): 463.72K
• Price to Earnings (P/E): 24.9
• Beta (1Y): 0.80
• Revenue Growth: 25.30%
• EPS Growth: N/A
• Country: IL
• Employees: 936
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Care Facilities
• EPS (TTM): 0.20
• Shares Outstanding: 510,874,760
• 10 Day Avg. Volume: 429,606
• 30 Day Avg. Volume: 463,716
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: 155.00 ▲(10.71% Upside)

Novolog's strong revenue growth and stable financial position are key strengths, while technical indicators suggest moderate stock momentum. The high dividend yield enhances value, though the P/E ratio indicates moderate valuation. Attention to cash flow and equity trends is advised.

Novolog Business Overview & Revenue Model

Company Description

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.

How the Company Makes Money

Novolog makes money primarily through service fees charged for its logistics and supply chain management services. The company's revenue model includes charging clients for warehousing and storage solutions, transportation and distribution services, and supply chain consultancy. Novolog may also generate income from value-added services such as temperature-controlled logistics and inventory management solutions. Strategic partnerships with pharmaceutical companies and healthcare providers play a crucial role in securing long-term contracts, providing a steady stream of revenue. Additionally, Novolog's investment in technology enables it to offer data-driven insights and analytics services, which can be an additional source of income.

Novolog Financial Statement Overview

Summary

Novolog demonstrates strong revenue growth and stable operations. However, profitability metrics and free cash flow volatility indicate potential areas for improvement. Manageable leverage and strong operating cash flows are positives.

Income Statement

Novolog shows a consistent revenue growth trend with a notable 19.5% increase from 2021 to 2022, continuing to 8% in 2023. Gross profit margins remain stable around 8-11%. Despite fluctuations in EBIT and net income, the TTM data indicates a recovery in net profitability. However, net profit margins are relatively low, highlighting room for efficiency improvements.

Balance Sheet

The company's debt-to-equity ratio is moderate, reflecting manageable leverage, but equity has been decreasing over recent periods. The equity ratio is around 12%, indicating a lower proportion of equity funding. Return on equity shows improvement but remains a potential area for strengthening to enhance shareholder value.

Cash Flow

Operating cash flow is strong relative to net income, suggesting robust cash generation capabilities. However, free cash flow has shown volatility, turning negative in the latest TTM period, which raises concerns about sustaining capital expenditures and returning value to shareholders.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.02B	1.64B	1.51B	1.26B	1.13B
Gross Profit	180.78M	173.76M	176.15M	148.96M	129.29M
EBITDA	149.39M	130.14M	138.53M	115.92M	104.05M
Net Income	39.54M	-42.00M	47.51M	42.32M	40.07M
Balance Sheet
Total Assets	3.04B	2.79B	2.43B	2.29B	2.19B
Cash, Cash Equivalents and Short-Term Investments	247.60M	232.94M	172.81M	238.71M	176.44M
Total Debt	198.47M	215.18M	212.77M	166.81M	154.24M
Total Liabilities	2.65B	2.39B	1.97B	1.86B	1.89B
Stockholders Equity	368.38M	371.08M	436.00M	424.37M	294.69M
Cash Flow
Free Cash Flow	99.78M	129.06M	63.16M	52.75M	32.87M
Operating Cash Flow	158.52M	200.01M	132.65M	83.39M	58.48M
Investing Cash Flow	-50.55M	-72.60M	-124.95M	-69.07M	-28.61M
Financing Cash Flow	-94.59M	-67.71M	-72.96M	47.49M	-39.85M

Novolog Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 140.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Negative. The current price of 140 is below the 20-day moving average (MA) of 141.11, below the 50-day MA of 140.64, and below the 200-day MA of 159.15, indicating a bearish trend. The MACD of -1.11 indicates Positive momentum. The RSI at 48.47 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NVLG.

Novolog Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVLG	66 Neutral	710.12M	24.87		5.59%	25.30%	―
Sector *	47 Neutral	C$187.86M	-2.63	-23.77%	3.19%	17.01%	2.49%
BRSYF	―	$227.28M	55.40	7.41%	―	―	―
ILX	―	675.20M	19.76		203.25%	―	―
DANE	57 Neutral	2.73B	107.87		2.02%	9.32%	―
REKA	―	135.72M	52.34		―	―	―
SOFW	65 Neutral	884.68M	―		―	17.69%	14.51%

Novolog Corporate Events

Novolog Updates Securities Registry Amid Strategic Option Exercises

Novolog has announced a change in its securities registry due to the exercise of employee options and the allocation of options to the Chairman of the Board. These changes include an increase in the number of securities and a private allocation to Altshuler Shaham Benefits Ltd., reflecting a strategic move to manage corporate shares and options effectively, potentially impacting shareholder value and market perception.

Novolog Announces Major Change in Securities Holdings

Novolog has reported a significant change in the holdings of securities, with Arie Schor, an interested party, increasing his holdings through a private placement. The change involved a single transaction resulting in an acquisition of 2,317,915 securities, now accounting for 100% of the current type of securities held. This adjustment reflects strategic positioning and could impact Novolog’s market dynamics by potentially influencing voting power and capital structure.

Novolog Announces Dividend Distribution for Shareholders

Novolog has announced a dividend distribution for its shareholders, with a record date of February 16, 2025. The company will distribute dividends at a rate of 0.44% to shareholders, which will be paid in cash, reflecting its adherence to its profit distribution policy.

Novolog Approves New Terms for Chairman’s Employment

Novolog held a special meeting to approve the terms of service and employment for the company’s Chairman of the Board, Mr. Arik Shor. The meeting, which required a regular majority for approval, concluded with the decision to approve the terms as outlined. This decision reflects an important operational update for Novolog, potentially affecting its governance structure and ensuring clarity in leadership roles.